Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016', provides in depth analysis on Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - The report reviews Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Overview 7 Therapeutics Development 8 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Products under Development by Stage of Development 8 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Products under Development by Therapy Area 9 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Products under Development by Indication 10 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Products under Development by Companies 14 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 23 Anacor Pharmaceuticals, Inc. 23 Astex Pharmaceuticals, Inc. 24 BioAxone BioSciences, Inc. 25 HitGen LTD 26 Kadmon Corporation, LLC 27 Vertex Pharmaceuticals Incorporated 28 Vichem Chemie Research Ltd. 29 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Drug Profiles 30 AN-3485 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 AT-13148 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 BA-1049 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 KD-025 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 KL-00148 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 KL-00199 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecule to Inhibit Rho-associated protein kinase 2 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 TRN-101 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 VX-210 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Dormant Projects 46 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Discontinued Products 47 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Featured News & Press Releases 48 Jun 03, 2016: Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Idiopathic Pulmonary Fibrosis 48 Mar 21, 2016: Kadmon Announces Publication of Data Demonstrating the Potential of ROCK2 Inhibition to Treat Chronic Graft-Versus-Host Disease 48 Feb 25, 2016: Kadmon to Present Preclinical Data Demonstrating ROCK2 Signaling as a Key Regulator of T Follicular Helper Cell Function in Autoimmune Conditions 49 Feb 08, 2016: BioAxone BioSciences Announces NIH/SBIR Fast Track Grant to Develop BA-1049 for Treatment of Cerebral Cavernous Malformation/Angioma 50 Jan 11, 2016: Kadmon to Present Preclinical Data Demonstrating the Importance of ROCK2 Signaling in Modulating Immune Response 51 Jun 22, 2015: Kadmon Presents Data Demonstrating Potential of ROCK2 Inhibition to Treat Lupus 51 May 06, 2015: Kadmon Presents Data on Role of ROCK2 Inhibition at AAI Annual Meeting 52 Feb 09, 2015: Kadmon Announces Publication Highlighting Importance of ROCK2 in Autoimmunity 53 Jan 06, 2015: Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Psoriasis 53 Dec 11, 2014: Kadmon Corporation's KD025 Named a Top Priority Lupus Treatment Candidate by the Alliance for Lupus Research and the Lupus Research Institute 54 Dec 08, 2014: Kadmon Corporation Presents Preclinical Data on KD025 in Chronic Graft-Versus-Host-Disease at American Society of Hematology Annual Meeting 54 Nov 10, 2014: Kadmon Researchers Define Importance of ROCK2 Signaling Pathway in Human Autoimmune Response 55 May 05, 2014: Kadmon Corporation Presents Results of KD025 Preclinical and Clinical Studies at AAI Annual Meeting 56 Apr 08, 2014: Kadmon Corporation Announces the Initiation of KD025 Phase 2 Program in Psoriasis 56 Mar 27, 2014: Kadmon Corporation Presents Results at the 9th International Congress on Autoimmunity Demonstrating the Effects of KD025 on Immune Homeostasis 57 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Development by Companies, H1 2016 (Contd..1) 16 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Mechanism of Action, H1 2016 18 Number of Products by Stage and Route of Administration, H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 22 Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 23 Pipeline by Astex Pharmaceuticals, Inc., H1 2016 24 Pipeline by BioAxone BioSciences, Inc., H1 2016 25 Pipeline by HitGen LTD, H1 2016 26 Pipeline by Kadmon Corporation, LLC, H1 2016 27 Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 28 Pipeline by Vichem Chemie Research Ltd., H1 2016 29 Dormant Projects, H1 2016 46 Discontinued Products, H1 2016 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
